WASHINGTON (dpa-AFX) - Edwards Lifesciences Corp. (EW) said it intends to
complete a spin-off of Critical Care at the end of 2024. It reaffirmed its 2023
financial guidance and provided guidance for 2024. The company's board approved
$1 billion of additional share repurchase authorization.

The company noted that the planned separation of Critical Care unit will enable
sharpened focus as the company pursues expanded opportunities for TAVR, TMTT and
Surgical patients, as well as new investments in interventional heart failure
technologies. Katie Szyman, Corporate Vice President of Critical Care since
2015, will be Chief Executive Officer of the new company upon completion of the
transaction.

The company expects 2024 adjusted earnings per share to be in the range of $2.70
- $2.80. Analysts polled by Thomson Reuters expects the company to report
earnings of $2.80 per share for fiscal year 2024. Analysts' estimates typically
exclude special items.

The company projects 2024 global sales of $6.3 billion - $6.6 billion,
representing a constant currency growth of 8% - 10%. Analysts expect revenue of
$6.51 billion for the fiscal year 2024.



Copyright(c) 2023 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX